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ABSTRACT
Introduction: Acute bacterial skin and skin
structure infections (ABSSSIs) are frequently
treated in emergency departments (EDs) or
observation units (OUs) initially with
intravenous (IV) antibiotics before discharge
on oral therapy. This study aims to describe
ABSSSI patients discharged directly from EDs/
OUs.
Methods: This is a retrospective cohort study of
patients with ABSSSIs treated in EDs/OUs of the
Detroit Medical Center from 2012 to 2014.
Adults with less than 24 h of IV antibiotics
without hospital admission were included.
Demographics, clinical characteristics, and
severity were compared between ED and OU
patients. Resource utilization, including tissue
and blood cultures, and use of radiographic
analysis was also collected. The primary
outcome was 96-h ED revisit/hospitalization.
Results: Analysis included 308 patients; 219 ED
and 89 OU. OU patients were significantly more
likely to be obese, have COPD/asthma, be
diagnosed with cellulitis, and meet at least one
systemic inflammatory response syndrome
(SIRS) criterion. Tissue cultures were obtained
in 21.7% of abscesses in the ED; 67.9% were in
uncomplicated abscesses. In the OU tissue
cultures were obtained in 48.8% of abscesses
and 37.5% were uncomplicated cases. Blood
cultures were drawn in 18.3% of ED patients
and 56.2% of OU patients, not significantly
associated with the presence of SIRS criteria.
Radiology was used in the diagnosis of ABSSSIs
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in 33.5% of ED versus 69.5% OU patients
(p\0.001), Plain film radiograph being the
most common. Thirty patients revisited the
ED or required hospitalization within 96 h, 23
from the ED (p = 0.479). Prior history of ABSSSI
(adjusted odds ratio [aOR] = 2.382, 95%
confidence interval [CI] 1.264–6.346) and
location on torso/buttocks (aOR = 2.355, 95%
CI 1.067–5.197) were independent predictors.
Conclusions: The low rate of ED revisit/
hospitalization supports the use of OUs for
low acuity ABSSSIs requiring initial IV therapy.
Resource utilization within EDs/OUs for the
management of ABSSSIs needs to be evaluated
for unnecessary testing/procures.
Keywords: Acute bacterial skin and skin
structure infections; Emergency department;
Intravenous antibiotics; Observation unit
INTRODUCTION
Acute bacterial skin and skin structure
infections (ABSSSIs) are among the most
common infections encountered in both
community and hospital settings [1, 2].
According to the 2010 National Hospital
Ambulatory Medical Care Survey (NHAMCS),
diseases of the skin and subcutaneous tissue
account for 4.2% of all emergency department
(ED) visits in the United States [3]. Additionally,
national trends indicate that the rate of ABSSSIs
has increased by approximately 50% since 1997,
with the majority of patients being treated and
released directly from the ED [4, 5]. There is a
wide clinical spectrum of ABSSSIs, from simple
uncomplicated abscesses to life-threatening
necrotizing fasciitis, and agreement upon
severity classification is lacking [6]. Most
ABSSSIs, aside from gangrene and fasciitis, are
treated on an outpatient basis. Although the
majority of patients receive care in the ED and
are not admitted, complications due to ABSSSIs
often lead to hospitalization. It is not presently
known how many revisits/admissions are
represented among the over 600,000 to
800,000 documented admissions for ABSSSIs in
the U.S. annually [2]. Two Canadian studies
have reported outpatient failure rates, resulting
in subsequent admission, of approximately
20–25% for cellulitis exclusively treated in the
ED [7, 8].
In a study by Edelsberg and colleagues,
antibiotic clinical failure rates were
documented for over 10,000 hospitalized
patients, 22.8% of all patients studied [2]. This
was mirrored by Berger and colleagues follow-
up study, which demonstrated failure rates of
16.6–34.1% [9]. These results demonstrated that
patients who initially fail empiric treatment
often require prolonged hospital stays and
intravenous (IV) antibiotics. Alternatively,
some patients are observed in the hospital for
short periods of time, either as brief admissions
or in observation units (OUs). According to the
American College of Emergency Physicians
(ACEP), 70% of patients selected from
treatment in OUs should be discharged before
24 h of care [10]. The use of these OUs allows for
hospital avoidance, decreased resource
utilization, and decreased exposure to the
healthcare environment, and thus a decrease
in adverse events. The use of observation status
has increased by 26% among Medicare
beneficiaries since 2008 [11]. Despite the high
incidence of ABSSSIs treated without hospital
admission, data examining the burden of
illness, processes of care, and decisions used to
determine care are lacking [12–14]. In addition,
many professional societies, including ACEP,
are advocating for more evidence-based,
conscientious use of diagnostic resources to
optimize care and decrease waste within
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healthcare [15]. The objectives of this study
were to determine the burden of illness and
services received for patients with less than 24 h
of IV therapy for ABSSSIs before being
discharged directly from EDs and OUs.
METHODS
Study Design
This retrospective observational study was
completed at the Detroit Medical Center
(DMC) between April 2012 and September
2014. Institutional Review Board approval was
obtained from Wayne State University with a
waiver of informed consent.
Study Setting and Population
The study was conducted at the DMC. The DMC
consists of nine hospitals and is the largest
healthcare provider for Southeast Michigan.
The study was completed at two acute care
trauma institutions (Detroit Receiving Hospital
and Harper University Hospital) and two
community-based hospitals (Sinai-Grace
Hospital and Huron Valley Sinai Hospital)
within the DMC.
Study Protocol
Patients were screened consecutively using a
standardized approach throughout the study
period and data was collected retrospectively,
after completion of care. Eligible patients were
those between 18 and 89 years of age diagnosed
with ABSSSI per the treating physician and
presenting with at least three of the following
local signs/symptoms: pain, tenderness,
swelling erythema, warmth, drainage/
discharge, induration, and/or lymph node
swelling/tenderness.
Patients were excluded from analysis if
osteomyelitis/septic arthritis, gas gangrene/
necrotizing infections were suspected.
Additional exclusion criteria included the
presence of prosthetic hardware or invasive
devices suspected to be the source of infection
but could not be removed, receiving oral
antibiotics only, treatment with IV antibiotics
for greater that 24 h, odontogenic infections,
open burn of greater than 30% of body surface
area, pregnant or nursing, or prisoners. For
patients with multiple eligible visits during the
study period, only the first was included as the
index visit. Patients were categorized as
receiving care in the ED if all management for
the index visit was received within the ED;
patients were categorized as receiving care in
the OU if they received any services in the OU
prior to discharge home.
Measures
Patient-level data collected included
demographics, comorbid conditions and
Charlson Comorbidity Score, antibiotic history
(last 90 days) and hospitalization history (last
180 days) as available, history of ABSSSI as
available, type of ABSSSI per Food and Drug
Administration definitions [16], complicated
versus uncomplicated ABSSSI [1, 17], criteria
for systemic inflammatory response syndrome
(SIRS), empiric treatment, other therapeutic
interventions for ABSSSI (debridement,
incision and drainage, amputation),
procedures and tests used to aid in the
diagnosis of ABSSSI, discharge antibiotic
prescription(s), type of insurance, time (in h)
till discharge from ED or OU, and 96-h ED
revisit/hospitalization. Two previously
published severity-scoring systems that have
been studied in the management of ABSSSIs
were also calculated and compared: the Clinical
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Resource Efficiency Support Team (CREST)/Eron
Classification and Standardized Early Warning
Score (SEWS) (Fig. 1) [18, 19]. The primary
outcome of interest was ‘‘early’’ ED revisit or
hospital admission, noted to be within 96-h
post-initial encounter [20].
Data Analysis
Descriptive statistics were determined for patient
demographics, comorbid conditions, severity
of illness per CREST/Eron and SEWS,
services/diagnostic procedures received, and
outpatient antibiotics prescribed. Characteristics
were compared between ED and OU patients to
determine possible differences in the treatment
pattern. Student t test, Mann–Whitney U test, or
Wilcoxon rank sum test was used for continuous
and ordinal variables and Pearson’s Chi-squared
or Fisher’s exact test was used for categorical
variables. Correlations were determined through
Spearman Rank-Order Correlation. A
multivariable logistic regression analysis was
conducted to determine independent risk
factors for the primary outcome of interest.
Variables significantly associated with the
outcome on univariate analysis (p B 0.1) or with
clinical and scientific rationale were included in
the explanatory model using backwards-stepwise
logistic regression. Data analysis was conducted
using SPSS Statistics (Version 22.0. Armonk, NY:
IBM Corp.).
CREST CLASSIFICATION
Systemic Toxicity Comorbidities Oral vs. IV Outpatient vs. Inpatient
CREST I No signs None Oral Outpatient




IV Hospital for 48hthen outpatient
CREST III




CREST IV Sepsis syndrome Unstable IV +/- surgical debridement Hospital
Standardized Early Warning System
Parameter Score
3 2 1 0
Respiratory (breaths/m) < 8 or > 36 31 - 35 21 - 30 9 - 20
Oxygen saturation  (%) <85 85 - 89 90 - 92 > 92
Temperature (°C) < 34 34 - 34.9 or > 38.5 35 – 35.9 or 38 – 38.4 36 - 37.9
Systolic BP (mmHg) < 69 70 - 79 or > 200 80 – 99 100 - 199
Heart rate (bpm) < 29 or > 130 30 - 39 or 110 - 129 40 – 49 or 100 - 109 50 - 99
Responsiveness Unresponsive Painful stimuli Verbal stimuli Alert
Fig. 1 Clinical Resource Efﬁciency Support Team (CREST) Classiﬁcation and Standardized Early Warning System
(SEWS) Score (adapted from [1, 18, 23])
176 Infect Dis Ther (2015) 4:173–186
This was an institutional review board
approved, retrospective, observational study at
an urban, academic medical center. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was waived by Wayne
State University institutional review board.
RESULTS
In total, 1877 patients’ electronic medical
records were reviewed for study inclusion, of
these 1569 were excluded from the current
study. Reasons for exclusion are detailed in
Fig. 2. The remaining 308 were included in the
final analysis, with 219 (71.1%) treated in the
ED and 89 (28.9%) sent to the OU. Patient
characteristics varied considerably according to
setting of care (Table 1). Uncomplicated
abscesses were often managed in the ED while
cellulitis was more commonly treated in the
OU. Patients with comorbid conditions such as
obesity (BMI C30 kg/m2) or asthma/COPD were
more likely to have a stay in the OU (p = 0.05,
p = 0.008, respectively). Criteria for SIRS, except
for temperature, were also significantly
associated with OU treatment. Socioeconomic
factors, such as insurance, had no significant
impact on setting of care.
One hundred and six (80.4%) ED patients
and 66 (74.2%) OU patients were determined to
be CREST/Eron Class I, suggesting treatment
with oral antibiotics on an outpatient basis
would be appropriate. The remainder were Class
II, indicating a short observation period with IV
antibiotics is appropriate. There was no
significant correlation between CREST/Eron
Class and setting of care. The median
(interquartile range) SEWS was 0 (0–1) for ED
patients and 1 (0–1) for OU patients and this
was significantly correlated with setting of care
(p = 0.01). Patients with a SEWS score C1 were
almost twice as likely to be treated in the OU
compared to the ED (odds ratio [OR] 1.96, 95%
confidence interval [CI] 1.17–4.13, p = 0.017).
Not surprisingly, there were also
considerable differences in the management
and utilization of resources in patients treated
in the ED compared to the OU, where patients
received care for a longer period of time
(median 20.56 versus 3.46 h) and were
overseen primarily by Internal Medicine
physicians. An important difference was the
collection of cultures from purulent lesions. Of
the 129 ED patients with purulent lesions, 28
(21.7%) had cultures obtained, 67.9% of these
were collected from uncomplicated abscesses.
In the OU cultures were obtained in 16 of 33
(48.8%) of purulent lesions, with 37.5% from
uncomplicated cases. Blood cultures were
drawn from 40 (18.3%) ED patients and 50







Excluded n = 1,569
> 24 hours n = 93
Odontogenic n = 18
Oral antibiotics n = 190
Gangrene n = 100
Hardware n = 72
Osteomyelitis n = 255
Hospitalization n = 506
Incomplete data n = 62
Repeat Visit n = 229
Pregnant/nursing n = 10
Prisoner n = 4
Age < 18 n = 6
Fig. 2 Study Consolidated Standards of Reporting Trials
(CONSORT)
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Table 1 Demographics by setting of care
Characteristics Emergency department (n5 219) Observation unit (n 5 89) p value
Age, median (IRQ) 41 (28–50) 46 (33–55) 0.083a
Male sex 121 (55.3) 42 (47.2) 0.143
Charlson score, median (IQR) 1 (0–2) 1 (0–2) 0.539a
Comorbidities
Diabetes mellitus 31 (14.2) 19 (21.3) 0.121
Obesity (BMI C30 kg/m2) 23 (10.5) 17 (19.1) 0.042
Chronic kidney disease 12 (5.5) 1 (1.1) 0.118b
Liver disease 5 (2.3) 5 (5.6) 0.159b
COPD/asthma 16 (7.3) 16 (18.0) 0.005
Injection drug use 23 (10.5) 11 (12.4) 0.637
Peripheral vascular disease 6 (2.7) 0 (0.0) 0.115b
Prior MRSA infection 4 (1.8) 3 (3.4) 0.410b
Prior history of ABSSSI 42 (19.2) 23 (25.8) 0.194
Prior hospitalization, 180 days 15 (6.8) 10 (11.2) 0.201
Prior antibiotics, 90 days 30 (13.7) 20 (22.5) 0.058
Primary location of ABSSSI 0.004
Head/neck 48 (21.9) 6 (6.7) 0.001
Hand 18 (8.2) 13 (14.6) 0.091
Arm 37 (16.9) 18 (20.2) 0.489
Leg 35 (16.0) 26 (29.2) 0.008
Foot 14 (6.4) 6 (6.7) 0.910
Trunk/buttocks 65 (29.7) 20 (22.5) 0.200
SIRS at presentation
Fever (temperature C38.0 C) 46 (21.0) 23 (25.8) 0.356
WBC[11,000 or\4000 15 (6.8) 15 (16.9) 0.007
Heart rate C90 beats/min 84 (38.4) 53 (59.6) 0.001
Respiratory rate C 20/min 5 (2.3) 9 (10.1) 0.003b
Insurance type
Medicaid 64 (29.2) 32 (36.0) 0.248
Medicare 26 (11.9) 7 (7.9) 0.303
Private 38 (17.4) 18 (20.2) 0.553
None 81 (37.0) 23 (25.8) 0.061
ABSSSI acute bacterial skin and skin structure infection, BMI body mass index, COPD chronic obstructive pulmonary
disease, IQR interquartile range, MRSA methicillin-resistant Staphylococcus aureus, WBC white blood cell count
a Wilcoxon rank sum test
b Fisher’s exact test
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between the presence of systemic toxicity (SIRS)
or comorbid conditions and the use of blood
cultures. Radiology was used to aid in the
diagnosis of ABSSSIs in 69 (31.5%) of ED and
59 (66.3%) of OU patients (p\0.001), the
majority (89.5%) through plain-film
radiograph, followed by ultrasound (7.5%) and
CT (5.2%). There was no significant difference
in the use of radiology in complicated versus
uncomplicated infections, either abscesses
(30.1% versus 32.3%) or cellulitis (53.5%
versus 63.4%). Initial laboratory assessment
was obtained in all patients; C-reactive protein
and erythrocyte sedimentation rate were not
routinely measured.
The most common empiric IV antibiotics
were clindamycin, vancomycin, and
ampicillin/sulbactam, respectively (Table 2).
Patients with abscesses, both complicated and
uncomplicated, were significantly more likely to
receive clindamycin in the ED (p = 0.001) while
vancomycin was more common in
uncomplicated abscesses and cellulitis in the
OU (p = 0.001 and 0.033, respectively). The
most common discharge antibiotics were
oral clindamycin and trimethoprim/
sulfamethoxazole (TMP/SMX) in both the ED
and OU. More patients with complicated
abscesses in the ED compared to OU received
an agent providing empiric coverage for
community acquired methicillin-resistant
Staphylococcus aureus (CAMRSA) (TMP/SMX,
clindamycin, and doxycycline) (p = 0.019).
Among patients with cellulitis, 88 (71.0%) were
prescribed an agent active against CAMRSA. For
patients with uncomplicated abscesses that
underwent incision and drainage 64 (91.4%)
received a discharge antibiotic, primarily those
active against CAMRSA.
Thirty patients (9.7%) from the entire
cohort, 23 (10.5%) ED and 7 (7.9%) OU
experienced the primary endpoint of 96-h ED
revisit or hospitalization. Among the entire
cohort 30-day infection-related admission was
low (23, 7.5%), with no significant difference
between patients seen in the ED versus OU.
Univariate analysis (Table 3) demonstrated that
prior history of ABSSSI, prior history of MRSA,
meeting SIRS criteria for alteration in body
temperature, and ABSSSI located on the torso/
buttocks were risk factors for 96-h ED revisit.
Due to the limited number of subjects
experiencing the primary outcome, only these
variables were tested in the regression model.
Through multivariable backwards-logistic
regression (Table 4), prior history of ABSSSI
(adjusted odds ratio [aOR] 2.38 [95% CI
1.26–6.35]) and location on the torso/buttocks
(aOR 2.36 [95% CI 1.07–5.20]) were
independently associated with 96-h ED revisit
or hospitalization. Among the subset of patients
managed only in the ED, prior history of ABSSSI
(aOR 3.03 [95% CI 1.19–7.80]) and meeting SIRS
criteria for temperature (aOR 2.51 [95% CI
1.00–6.35]) were independently associated
with 96-h ED revisit or hospitalization.
DISCUSSION
The types of ABSSSIs seen in EDs and OUs are
diverse and there is a high degree of variability
in the management strategies employed. Our
study demonstrated that patients with
complicated infections, especially cellulitis or
infections involving the leg, and presence of at
least one of the SIRS criteria, excluding
temperature alterations, were more likely to
have been upgraded to the OU. Ninety-six-hour
ED revisit or hospitalization was relatively
uncommon with only 9.7% of the entire
cohort experiencing this endpoint. This is
likely a reflection of the overall low acuity of
these patients. Few parameters were associated
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with 96-h ED revisit or hospitalization upon
multivariable analysis. Of note, a history of
recurring ABSSSIs as well as prior MRSA
infection were linked to the primary outcome.
One factor that has previously been shown to
increase risk of outpatient failure is meeting
SIRS criteria [21]. Based on this, the Infectious
Diseases Society of America (IDSA) guidelines
recommend initial inpatient management for
patients with SIRS criteria. A study by Volz and
colleagues found that patients with infections
on their hands were three times more likely to
require escalation of care [22]. Additionally, a
white blood cell count C15,000/mm3 and
female gender have been independently
associated with failure to be successfully
discharged from the OU [12]. The presence of
fever (temperature C38 C) was the most
commonly reported predictor for requiring a
hospital stay of C24 h or failure of ED/OU status
[13, 22]. In our cohort, the presence of fever was
found to be significantly linked to 96-h ED
revisit/admission among those treated in the
ED, likely a signal of requiring upgrade to the
OU. Future research should aim to determine if
these parameters can be generally applied to
determine which patients are likely to require
escalation of care to avoid subsequent ED
revisits.
Severity of illness was evaluated using two
scoring systems not commonly employed in the
United States—the CREST/Eron Classification
and the SEWS [18, 19]. These systems were
employed because there is currently not a
commonly used or validated tool in the
United States. Neither correlated with site of
care, suggesting that the management decisions
in the ED/OU setting for ABSSSI are likely based
Table 2 Antimicrobial therapy by setting of care (emergency department versus observation unit)
Antibiotic Emergency department (n5 219) Observation unit (n5 89) p value
Empiric IV therapy
Empiric vancomycin 31 (14.2) 35 (39.3) \0.001
Empiric clindamycin 128 (58.4) 26 (29.2) \0.001
Empiric ampicillin/sulbactam 37 (16.9) 19 (21.3) 0.415
Discharge antibiotic
Amoxicillin/clavulanate 19 (8.7) 12 (13.4) 0.214
Cephalexin 41 (18.7) 7 (7.8) 0.049
Clindamycin 106 (48.4) 30 (33.7) 0.027
Doxycycline 8 (3.7) 1 (1.1) 0.455b
Linezolid 1 (0.5) 1 (1.1) 0.495b
None 16 (7.3) 18 (20.2) 0.002
TMP/SMX 17 (7.8) 22 (24.7) \0.001
Dual therapya 36 (16.4) 8 (9.0) 0.107
CAMRSA community acquired methicillin-resistant Staphylococcus aureus, IV intravenous, TMP/SMX trimethoprim–
sulfamethoxazole
a Coverage of CAMRSA and streptococcal species
b Fisher’s exact test
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Table 3 Univariate analysis of 96-h revisit or hospital admission
Characteristics 96 h revisit (n5 30) No revisit (n5 278) p value
ED setting of care 23 (76.7) 19 (70.5) 0.479
CREST/Eron class II 8 (26.7) 57 (20.5) 0.701
Comorbid conditions
Diabetes 6 (20.0) 44 (15.8) 0.566
Prior ABSSSI 12 (40.0) 53 (19.1) 0.008
Prior MRSA infection 3 (10.0) 4 (1.4) 0.003a
Morbid obesity 6 (20.0) 34 (12.2) 0.250
Charlson comorbidity score (IQR) 1.0 (0.0–1.3) 1.0 (0.0–2.0) 0.601
Surgical intervention 12 (40.0) 137 (49.3) 0.345
Antibiotics 90 Days 3 (10.0) 47 (16.9) 0.382
SIRS criteria on presentation
Body temp[38 or\36 11 (36.7) 28 (20.9) 0.049
HR[90 beats/min 14 (46.7) 123 (44.2) 0.800
RR[20 breaths/min 1 (3.3) 13 (4.7) 1.000a
WBC[12,000 or\4000 4 (13.3) 26 (9.4) 0.485
Site of infection
Arm 3 (10.0) 52 (18.7) 0.319a
Leg 7 (23.3) 54 (19.4) 0.631
Head/neck 3 (10.0) 51 (18.3) 0.320
Buttocks/torso 13(43.3) 72 (25.9) 0.042
Hand 1 (3.3) 30 (10.8) 0.197a
Foot 3 (10.0) 17 (6.1) 0.427a
Type of ABSSSI
Complicated cellulitis 3 (10.0) 35 (12.6) 0.682a
Complicated abscess 6 (20.0) 57 (20.5) 0.948
Uncomplicated cellulitis 9 (30.0) 77 (27.7) 0.789
Uncomplicated abscess 11 (36.7) 88 (31.7) 0.577
Empiric antibiotics
Ampicillin/sulbactam 3 (10.0) 53 (19.1) 0.319a
Discharge antibiotics
Combination therapy 6 (20.0) 38 (13.7) 0.408
Tissue culture available 6 (20.0) 49 (17.6) 0.802
ABSSSI acute bacterial skin and skin structure infection, CREST Clinical Resource Efﬁciency Support Team, HR heart rate,
IQR interquartile range, MRSA methicillin-resistant Staphylococcus aureus, RR respiratory rate, WBC white blood cell
a Fisher’s exact test
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on factors not included in current criteria.
Comorbid conditions requiring additional
management and optimization may be
influencing these decisions. Neither CREST/
Eron nor SEWS has been validated to
determine ABSSSI management in ED versus
OU specifically. Marwick and colleagues
observed that 70% of patients in CREST/Eron
Class II (normally recommended to treat as
inpatient with IV antibiotics for up to 48 h)
could be treated on an outpatient basis [19]. In
our study there was no significant difference in
the amount of CREST/Eron Class II patients
between ED and OU, supporting the previous
finding. Physiological parameters within SEWS
were better able to differentiate patients that
were upgraded to the OU, which also mirrors
findings from Marwick and colleagues in their
attempt to prospectively validate a modified
CREST/Eron Classification system [23]. Higher
CREST/Eron Class or SEWS were not associated
with 96-h ED revisit/hospitalization. Even
though severity scoring could potentially
identify patients requiring observation for a
period of up to 48 h, our results suggest that the
majority of patients, especially those with
uncomplicated cellulitis or abscess, do not
need this extended period of healthcare
exposure. Aligned with data on outpatient
parental antimicrobial therapy data (OPAT),
use of OUs with or without subsequent OPAT
can lead to reduced hospital costs, decreased
healthcare exposure and risk of adverse events,
and improve patient care [10, 24, 25].
Numerous investigations have examined the
appropriateness of antibiotic prescribing for
ABSSSIs in EDs, especially with the rising
prevalence of CAMRSA [26–29]. Pallin and
colleagues evaluated data form 2007–2010
NHAMCS using the quality measures of
overuse, underuse, and misuse. Overuse was
defined as use of any antibiotic for abscess
patients with successful incision and drainage
or use of CAMRSA agents in patients with
cellulitis (no purulence). In our study, over
80% of patients with incision and drainage were
prescribed antibiotics on discharge and over
60% of patients with cellulitis were prescribed
an agent active against CAMRSA. Double
coverage against both streptococcal spp. and
CAMRSA was also a common occurrence,
which increases the risk of adverse drug events
and resistance [30]. These data support the need
for improvement initiatives in prescribing
patterns for ABSSSIs.
Diagnostics procedures were significantly
different in patients treated in the ED versus
OU, which is not surprising based on the
difference in time receiving care and specialty
of the treating physicians. Routine blood
cultures, drawn in over 50% of OU patients,
have not been shown to improve clinical
Table 4 Multivariable regression analysis of risk factors for 96-h ED revisit or hospital admission
Factor Unadjusted OR 95% CI p value Adjusted OR 95% CI p value
Prior ABSSSI 2.83 1.29–6.23 0.013 2.38 1.26–6.35 0.014
Prior MRSA 7.61 1.62–35.79 0.020 4.38 0.80–24.20 0.072
Temperature[38 or\36 C 2.19 0.99–4.87 0.061 2.20 0.97–5.00 0.059
Location Torso/Buttocks 2.19 1.01–4.73 0.042 2.36 1.07–5.20 0.038
ABSSSI acute bacterial skin and skin structure infection, CI conﬁdence interval, OR odds ratio, MRSA methicillin-resistant
Staphylococcus aureus
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outcomes, and are not recommended routinely
by the IDSA for the treatment of skin and skin
structure infections [21, 31, 32]. The American
Board of Internal Medicine developed the
Choose Wisely Campaign to limit unnecessary
tests and procedures in the treatment of various
medical conditions [15]. ACEP, a partner
organization, lists the use of antibiotics and
cultures in uncomplicated abscesses after
incision and drainage with medical follow-up
among their top 10 unnecessary procedures and
tests [33]. Our data demonstrate that in the ED
over 60% of cultures were taken in
uncomplicated abscesses. It is important to
note, however, that due to the retrospective
nature of the study we cannot assess if
appropriate outpatient follow-up was available
or if the cultures and susceptibility data from
the ED was conveyed to each applicable patient.
Our findings are similar to Jenkins and
colleagues wherein arguably avoidable
healthcare resources were employed for
diagnostic testing [26]. Among the 322
inpatients included in their analysis, 47–58%
of patients had blood cultures drawn, of which
13 patients were bacteremic. Radiological data
were also commonly used to rule/out deeper
sites of infection. Among patients with
cellulitis, 94% received a plain film
radiograph, with a positive yield of only 1%. It
is important to note, however, that Jenkins and
colleagues studied hospitalized patients with
ABSSSSIs where our cohort was entirely treated
in the ED/OU setting.
Limitations
There are several limitations to this study that
should be addressed. First, the study was
retrospective in nature, and thus relied on
proper documentation within electronic
medical charts. This may be especially
important for history of MRSA and size of the
lesion. The study was also single centered,
which may limit the external generalizability
of the results. It is unclear what differences in
practice patterns or patient acuity may exist
among patients treated for ABSSSIs at other
institutions. In addition, the fact that DMC is
only one of several large academic medical
centers within the Detroit metropolitan area
makes it likely that some ED revisits were
missed. Much like the study with Pallin and
colleagues, patients with incision and drainage
may have been prescribed outpatient antibiotics
due to a large area of induration around the
lesion, thus falsely increasing the cases in our
quality measure of overuse [28]. The study
consists of patients treated with IV antibiotics
only, but the decision to administer IV versus
orally is also highly subjective and may
contribute to our inability to discern
differences between settings of care or 96-h ED
revisit/hospitalization. Lastly, resource
utilization for follow-up in ambulatory care
clinics was not evaluated.
CONCLUSION
Data regarding the decision strategies and
processes of care in patients with ABSSSIs with
low acuity, especially those treated in OUs, are
relatively unreported. This study demonstrated
the subjective nature of determining patient
level of care as well as the varied diagnostic
tests/procedures and prescribing patterns for
patients discharged with ABSSSIs. Resources
utilized in the diagnosis and management of
these lower acuity ABSSSIs should be critically
evaluated to determine necessity and benefit to
the patient. Additionally, few differences in
patient presentation were significantly linked
to the decision to escalate care to OU status.
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Across both settings, ED revisit or
hospitalization within 96 h was infrequent;
suggesting that short observation and less than
24 h of IV therapy followed by oral therapy is
appropriate management for many ABSSSIs,
particularly in patients with no prior history of
infection. Several considerations, such as past
history of ABSSSI, temperature alterations at
presentation, or certain locations of ABSSSIs
may be important indicators for need to escalate
care. There is, however, a need for more
evidence-driven guidance of patient
disposition and resources necessary to
optimize patient outcomes while decreasing
wasteful use of finite and costly resources.
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